Sihuan Pharma’s Fourth-Gen Insulin Degludec NDA Accepted by NMPA for Review
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its New Drug Application (NDA)...
Sihuan Pharma’s Anaprazole Enters Phase II Study for Reflux Esophagitis
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co.,...
Takeda Opens R&D Asia-Pacific Headquarters in Shanghai to Boost Drug Development
Japan’s Takeda Pharmaceutical Co., Ltd has inaugurated its R&D Asia-Pacific headquarters in Pudong, Shanghai. The...
Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development
Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has...
Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs
Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...
Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...
Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...
Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...
Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China
China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...
Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China
Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...
Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...
HutchMed Initiates Phase I Study of CD47 Monoclonal Antibody HMPL-A83 in China
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study...
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...
Fermion Secures Series B Financing to Advance AI-Driven Drug Development
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...
Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform
Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...
Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials
China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...
WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform
China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation...
ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has...
VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed
China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...
Merck KGaA Launches Uptune Program in Asia, Offers Startups Up to €100,000
Germany-based life sciences giant Merck KGaA has launched the Uptune program in Asia, offering up...